FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy
Related Topics >> Merck | Vioxx

Securities lawsuit up against Merck's Vioxx

Tools

In April 2007, Federal Judge Stanley Chesler dismissed an investor lawsuit seeking class-action status against Merck, but an appeals panel from the Third U.S. Circuit Court of Appeals reversed the ruling on Tuesday. Plaintiffs filed the original lawsuit in November 2003.

Judge Chesler originally said the statute of limitations was up, but the appeals panel disagreed.

Plaintiffs claim Merck was not straightforward about the risks of Vioxx. The plaintiff investors took a $30-billion dollar hit in 2004 when Merck withdrew Vioxx following news that the drug doubled the risk of heart attack or stroke. The securities lawsuit is distinct from personal injury lawsuits against Merck, which began paying claimants last month.

According to Merck, the statute-of-limitations rationale is not the only rationale for blocking the suit. For example, Merck says there were no strong data linking Vioxx to heart attacks or strokes at the time. The company will seek reversal based on alternative grounds if necessary.

- read the story at CNN Money
- see the Wall Street Journal's take
- here are the court documents

Related Articles:
Judge whacks Vioxx class action suit
NY double-teams Merck in Vioxx lawsuit
Judge throws out $50M Vioxx award

More stories about Merck   Vioxx  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 47 + 37?
To combat spam, please solve the math question above.